search
Back to results

Effects of Early Vitamin D3 Supplementation on Clinical Outcomes for Critically Ill Patients

Primary Purpose

Vitamin D Deficiency, Critical Illness

Status
Not yet recruiting
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Vitamin D
Medium Chain Triglycerides
Sponsored by
National Taiwan University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Vitamin D Deficiency focused on measuring vitamin D, calcidiol levels, critically ill

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: >18-year-old critically ill patient. Admission to ICU < 24 hours. APACHE II at 24 hours of admission to ICU ranged from 20-39 points. The basic blood calcifediol concentration within 24 hours of admission to the intensive care unit is < 20 ng/mL. Intensive care physician expects patient to stay in ICU for ≥ 72 hours. Exclusion Criteria: Hypercalcemia (total calcium ion concentration in blood > 2.6 mmol/L). Disorders affecting serum calcifediol concentration, calcium metabolism, or bone metabolism (eg, parathyroid disease, rickets, or severe cirrhosis [Child C]). Have received high-dose vitamin D3 therapy (> 2000 IU per day or ≥ 10,000 IU in a single dose) within four weeks. Admitted to the intensive care unit with a diagnosis of new coronary pneumonia (COVID-19). Organ transplant patients. Have had tuberculosis, sarcoidosis or kidney stones within a year. Kidney dialysis, continuous renal replacement therapy (Continuous Renal Replacement Therapy, CRRT), acute kidney injury (Acute kidney injury, AKI). Body weight <45 kg or >90 kg. Has been admitted to an intensive care unit within three months. Patients and family members who do not speak their native language. Pregnant women.

Sites / Locations

  • National Taiwan University Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Placebo Comparator

Placebo Comparator

Placebo Comparator

Experimental

Experimental

Experimental

Arm Label

Control1

Control2

Control3

Vitamin D1

Vitamin D2

Vitamin D3

Arm Description

Enteral supplement 8 ampoules Medium Chain Triglycerides if serum calcifediol level is 15-19.9 ng/mL.

Enteral supplement 10 ampoules Medium Chain Triglycerides if serum calcifediol level is 12-14.9 ng/mL.

Enteral supplement 12 ampoules Medium Chain Triglycerides if serum calcifediol level below 12 ng/mL

Enteral supplement 8 ampoules vitamin D(576000IU) if serum calcifediol level is 15-19.9 ng/mL.

Enteral supplement 10 ampoules vitamin D(720000IU) if serum calcifediol level is 12-14.9 ng/mL.

Enteral supplement 12 ampoules vitamin D(864000IU) if serum calcifediol level below 12 ng/mL

Outcomes

Primary Outcome Measures

Mortality
Mortality within 30 days

Secondary Outcome Measures

Full Information

First Posted
June 30, 2023
Last Updated
June 30, 2023
Sponsor
National Taiwan University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05937789
Brief Title
Effects of Early Vitamin D3 Supplementation on Clinical Outcomes for Critically Ill Patients
Official Title
Effects of Early Vitamin D3 Supplementation on Clinical Outcomes for Critically Ill Patients
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
July 1, 2023 (Anticipated)
Primary Completion Date
June 30, 2026 (Anticipated)
Study Completion Date
December 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Taiwan University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
There are no clear international guidelines for dosing vitamin D based on deficiency severity. Therefore, a new clinical trial is needed to evaluate the benefits of early vitamin D supplementation in maintaining sufficient levels for critically ill patients. Our group conducted a multicenter clinical trial in Taiwan focusing on vitamin D and critically ill patientsWe will enroll 240 patients with low calcidiol levels and provide varying supplementation doses to maintain their serum calcidiol levels ≥ 30 ng/mL within 30 days of ICU admission. The results will serve as a valuable reference for intensivists when formulating appropriate vitamin D treatment strategy to maximize clinical benefits for critically ill patients.
Detailed Description
Recent studies have highlighted a prevalent vitamin D deficiency in critically ill patients, ranging from 26% to 82%. These patients experience longer ICU stays, higher medical expenses, and increased sepsis-related mortality. Our group conducted a multicenter clinical trial in Taiwan focusing on vitamin D and critically ill patients. In the first phase, the epidemiological investigation found significantly lower serum calcidiol levels of approximately 20.9 ng/mL compared to the normal range of 30-60 ng/mL in ICU patients. The second phase, a randomized control study, preliminarily demonstrated that supplementing 576,000 IU of vitamin D3 in critically ill patients with serum calcidiol levels below 20 ng/mL significantly reduced the risk of multidrug resistant bacterial infections within 30 days. An Austrian trial also showed that adequate vitamin D supplementation lowered in-hospital mortality in severely deficient patients. The importance of vitamin D supplementation for critically ill patients with vitamin D deficiency is evident, as their clinical prognosis is closely related to achieving adequate serum calcidiol levels. However, there are no clear international guidelines for dosing vitamin D based on deficiency severity. Therefore, a new clinical trial is needed to evaluate the benefits of early vitamin D supplementation in maintaining sufficient levels for critically ill patients. We will enroll 240 patients with low calcidiol levels and provide varying supplementation doses to maintain their serum calcidiol levels ≥ 30 ng/mL within 30 days of ICU admission. The results will serve as a valuable reference for intensivists when formulating appropriate vitamin D treatment strategy to maximize clinical benefits for critically ill patients

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitamin D Deficiency, Critical Illness
Keywords
vitamin D, calcidiol levels, critically ill

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
240 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control1
Arm Type
Placebo Comparator
Arm Description
Enteral supplement 8 ampoules Medium Chain Triglycerides if serum calcifediol level is 15-19.9 ng/mL.
Arm Title
Control2
Arm Type
Placebo Comparator
Arm Description
Enteral supplement 10 ampoules Medium Chain Triglycerides if serum calcifediol level is 12-14.9 ng/mL.
Arm Title
Control3
Arm Type
Placebo Comparator
Arm Description
Enteral supplement 12 ampoules Medium Chain Triglycerides if serum calcifediol level below 12 ng/mL
Arm Title
Vitamin D1
Arm Type
Experimental
Arm Description
Enteral supplement 8 ampoules vitamin D(576000IU) if serum calcifediol level is 15-19.9 ng/mL.
Arm Title
Vitamin D2
Arm Type
Experimental
Arm Description
Enteral supplement 10 ampoules vitamin D(720000IU) if serum calcifediol level is 12-14.9 ng/mL.
Arm Title
Vitamin D3
Arm Type
Experimental
Arm Description
Enteral supplement 12 ampoules vitamin D(864000IU) if serum calcifediol level below 12 ng/mL
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D
Intervention Description
1ampoule (72000IU) Q3H on ICU day 3 Number of Cycles: until progression or subject develops severe diarrhea (greater than 1000 grams) associated with vitamin D supplementation for two consecutive days.
Intervention Type
Dietary Supplement
Intervention Name(s)
Medium Chain Triglycerides
Other Intervention Name(s)
MCT
Intervention Description
1ampoule Q3H on ICU day 3 Number of Cycles: until progression or subject develops severe diarrhea (greater than 1000 grams) associated with vitamin D supplementation for two consecutive days.
Primary Outcome Measure Information:
Title
Mortality
Description
Mortality within 30 days
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: >18-year-old critically ill patient. Admission to ICU < 24 hours. APACHE II at 24 hours of admission to ICU ranged from 20-39 points. The basic blood calcifediol concentration within 24 hours of admission to the intensive care unit is < 20 ng/mL. Intensive care physician expects patient to stay in ICU for ≥ 72 hours. Exclusion Criteria: Hypercalcemia (total calcium ion concentration in blood > 2.6 mmol/L). Disorders affecting serum calcifediol concentration, calcium metabolism, or bone metabolism (eg, parathyroid disease, rickets, or severe cirrhosis [Child C]). Have received high-dose vitamin D3 therapy (> 2000 IU per day or ≥ 10,000 IU in a single dose) within four weeks. Admitted to the intensive care unit with a diagnosis of new coronary pneumonia (COVID-19). Organ transplant patients. Have had tuberculosis, sarcoidosis or kidney stones within a year. Kidney dialysis, continuous renal replacement therapy (Continuous Renal Replacement Therapy, CRRT), acute kidney injury (Acute kidney injury, AKI). Body weight <45 kg or >90 kg. Has been admitted to an intensive care unit within three months. Patients and family members who do not speak their native language. Pregnant women.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yin Yi Han
Phone
0972651405
Email
noviahan@gmail.com
Facility Information:
Facility Name
National Taiwan University Hospital
City
Taipei
ZIP/Postal Code
100
Country
Taiwan

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effects of Early Vitamin D3 Supplementation on Clinical Outcomes for Critically Ill Patients

We'll reach out to this number within 24 hrs